[Chronic arterial occlusive diseases--drug therapy and thromboxane A2 synthetase inhibitor].
Yasuda
K
K
Department of Cardiovascular Surgery, Hokkaido University Hospital.
Matsui
Y
Y
Goda
T
T
Sakuma
M
M
Go
K
K
D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000378:metabolism; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D002908:Chronic Disease; D011464:Epoprostenol / Q000096:biosynthesis; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008689:Methacrylates / Q000494:pharmacology / Q000627:therapeutic use; D011089:Polydeoxyribonucleotides / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000096:biosynthesis / Q000494:pharmacology / Q000627:therapeutic use; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D005229:Fatty Acids, Monounsaturated; D008689:Methacrylates; D011089:Polydeoxyribonucleotides; D011725:Pyridines; C036901:defibrotide; D013928:Thromboxane A2; C049855:ONO 3708; D011464:Epoprostenol; D013930:Thromboxane-A Synthase; C045446:isbogrel; C034364:ozagrel; D001241:Aspirin